Doxorubicin Plus Dacarbazine Versus Doxorubicin Alone as First-Line Therapy for Metastatic or Recurrent Uterine Leiomyosarcoma

The goal of this clinical trial is to learn whether adding dacarbazine to doxorubicin works better than doxorubicin alone as the first drug treatment for women with uterine leiomyosarcoma that is metastatic or has come back after surgery. A total of 100 participants will be randomly assigned to receive either doxorubicin alone or doxorubicin plus dacarbazine for up to 6 cycles of 21 days each. Researchers will compare how many participants are alive without disease progression 1 year after the start of treatment.

Trial Details

NCT ID
NCT07942168
Phase
PHASE2
Sponsor
Blokhin's Russian Cancer Research Center
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Doxorubicin
  • dacarbazine
Locations (sample)
  • Moscow, Russia|55.75204,37.61781

Key Eligibility Criteria

  • Morphologically verified uterine leiomyosarcoma
  • Age 18 to 70 years
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Metastatic disease at diagnosis, or disease recurrence after prior surgical treatment for localized disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →